Welcome to Advanced Search

Models

About 196 results
Literature
Literature

A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy

Model Organisms:Mouse Product & Service:TIM-3 Research field:Cancer immunotherapy

Literature
Literature

Targeting IRG1 reverses the immunosuppressive function of tumor-associated macrophages and enhances cancer immunotherapy

Model Organisms:小鼠 Product & Service:Acod1-flox Research field:cancer immunotherapy

Literature

PHE1-based IgG-like antibody platform provides a novel strategy for enhanced T-cell immunotherapy

Model Organisms:小鼠 Product & Service:- Research field:

Pages

Workshop:Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Pages

SMOC Launched U-HuDTMbase®, Inclusive Resource Library of Innovative Therapeutic Target-Humanized Mouse Models, to Accelerate Novel Drug Discovery

U-HuDTMbase® is composed of more than 600 therapeutic target-humanized mouse models, including multiple background strains, and has covered almost all commonly studied areas, such as oncology, metabolism, immunity, inflammation and more.

Pages

Evaluating the Efficacy of Tumor-targeted Antibody in vivo

immunotherapy immune checkpoint immune checkpoint genes

As the most frequently used animal model, mice have been widely applied in the evaluation of drug efficacy. However, the human immune checkpoint genes only share ~60% identity with their murine counterparts. Thus antibodies that recognize human proteins do not necessarily interact with murine proteins, making it inappropriate to use wild type mice for evaluating the in vivo efficacy of human-specific antibody. The humanized immune checkpoint mouse models (Immune-Hu models), which were independently developed by Shanghai Model Organisms Center, are ideal models to evaluate the efficacy of anti-tumor antibody therapy.

Email Back to top